CoChat

Pharmacological Comparative Characterization of REL-1017 (Esmethadone-HCl) and Other NMDAR Channel Blockers in Human Heterodimeric N-Methyl-D-Aspartate Receptors

Open access

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Abstract

Excessive Ca2+ currents via N-methyl-D-aspartate receptors (NMDARs) have been implicated in many disorders. Uncompetitive NMDAR channel blockers are an emerging class of drugs in clinical use for major depressive disorder (MDD) and other neuropsychiatric diseases. The pharmacological characterization of uncompetitive NMDAR blockers in clinical use may improve our understanding of NMDAR function in physiology and pathology. REL-1017 (esmethadone-HCl), a novel uncompetitive NMDAR channel blocker in Phase 3 trials for the treatment of MDD, was characterized together with dextromethorphan, memantine, (±)-ketamine, and MK-801 in cell lines over-expressing NMDAR subtypes using fluorometric imaging plate reader (FLIPR), automated patch-clamp, and manual patch-clamp electrophysiology. In the absence of Mg2+, NMDAR subtypes NR1-2D were most sensitive to low, sub-μM glutamate concentrations in FLIPR experiments. FLIPR Ca2+ determination demonstrated low μM affinity of REL-1017 at NMDARs with minimal subtype preference. In automated and manual patch-clamp electrophysiological experiments, REL-1017 exhibited preference for the NR1-2D NMDAR subtype in the presence of 1 mM Mg2+ and 1 μM L-glutamate. Tau off and trapping characteristics were similar for (±)-ketamine and REL-1017. Results of radioligand binding assays in rat cortical neurons correlated with the estimated affinities obtained in FLIPR assays and in automated and manual patch-clamp assays. In silico studies of NMDARs in closed and open conformation indicate that REL-1017 has a higher preference for docking and undocking the open-channel conformation compared to ketamine. In conclusion, the pharmacological characteristics of REL-1017 at NMDARs, including relatively low affinity at the NMDAR, NR1-2D subtype preference in the presence of 1 mM Mg2+, tau off and degree of trapping similar to (±)-ketamine, and preferential docking and undocking of the open NMDAR, could all be important variables for understanding the rapid-onset antidepressant effects of REL-1017 without psychotomimetic side effects.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ph15080997

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 REL-1017 concentration-response curve (CRC) was performed in the presence of 10 µM L-glutamate and 10 µM glycine but in the absence of extracellular Mg2+ by fluorometric imaging plate reader (FLIPR) Ca2+ assay using Chinese hamster ovary (CHO) cell lines expressing the indicated heterodimeric N-methyl-D-aspartate receptors (NMDARs). REL-1017 caused a decrease in the increased intracellular Ca2+ elicited by 10 µM L-glutamate with estimated IC50 concentrations of 43 µM, 23 µM, 23 µM, and 68 µM for 2A-, 2B-, 2C-, and 2D-containing NMDARs, respectively. 100 μM REL-1017, the maximal tested concentration, reduced Ca2+ influx by 30%, 14%, 15%, and 47% of that evoked by 10 µM L-glutamate for NR1-2A, NR1-2B, NR1-2C, and NR1-2D subtypes, respectively. Fitting parameters for REL-1017 and other known NMDAR blockers, which were tested in identical conditions, are reported in Table 1. Data are mean ± standard error of the mean (SEM), n = 6 per group, and were fitted using the four-parameter logistic equation with GraphPad Prism v8.0. RFU is relative fluorescence units.
Figure 1 REL-1017 concentration-response curve (CRC) was performed in the presence of 10 µM L-glutamate and 10 µM glycine but in the absence of extracellular Mg2+ by fluorometric imaging plate reader (FLIPR) Ca2+ assay using Chinese hamster ovary (CHO) cell lines expressing the indicated heterodimeric N-methyl-D-aspartate receptors (NMDARs). REL-1017 caused a decrease in the increased intracellular Ca2+ elicited by 10 µM L-glutamate with estimated IC50 concentrations of 43 µM, 23 µM, 23 µM, and 68 µM for 2A-, 2B-, 2C-, and 2D-containing NMDARs, respectively. 100 μM REL-1017, the maximal tested concentration, reduced Ca2+ influx by 30%, 14%, 15%, and 47% of that evoked by 10 µM L-glutamate for NR1-2A, NR1-2B, NR1-2C, and NR1-2D subtypes, respectively. Fitting parameters for REL-1017 and other known NMDAR blockers, which were tested in identical conditions, are reported in Table 1. Data are mean ± standard error of the mean (SEM), n = 6 per group, and were fitted using the four-parameter logistic equation with GraphPad Prism v8.0. RFU is relative fluorescence units.CC BY · PubMed Central
Figure 2 REL-1017 effect on L-glutamate CRC was obtained in a FLIPR Ca2+ assay to estimate REL-1017 KB. REL-1017 KB is the equilibrium dissociation constant of the REL-1017 receptor complex and the REL-1017 concentration required to occupy 50% of the total NMDAR population. The graphs show L-glutamate CRCs alone (●) or in the presence of six different concentrations of REL-1017 (● 50 µM, ● 12.5 µM, ●3.1 µM, ● 781 nM, ● 195 nM, and ● 49 nM) using four different CHO cell lines expressing heterodimeric human NMDARs: NR1-2A, NR1-2B, NR1-2C, and NR1-2D. An operational equation for allosteric modulators was used to estimate REL-1017 KB and is reported in Table 2. The insurmountable antagonism demonstrated by REL-1017 is apparent from the graphs, as inhibition induced by high concentrations of REL-1017 (e.g., 50 µM) cannot be overcome even by agonist concentrations as high as 1 mM L-glutamate. RFU is relative fluorescence units.
Figure 2 REL-1017 effect on L-glutamate CRC was obtained in a FLIPR Ca2+ assay to estimate REL-1017 KB. REL-1017 KB is the equilibrium dissociation constant of the REL-1017 receptor complex and the REL-1017 concentration required to occupy 50% of the total NMDAR population. The graphs show L-glutamate CRCs alone (●) or in the presence of six different concentrations of REL-1017 (● 50 µM, ● 12.5 µM, ●3.1 µM, ● 781 nM, ● 195 nM, and ● 49 nM) using four different CHO cell lines expressing heterodimeric human NMDARs: NR1-2A, NR1-2B, NR1-2C, and NR1-2D. An operational equation for allosteric modulators was used to estimate REL-1017 KB and is reported in Table 2. The insurmountable antagonism demonstrated by REL-1017 is apparent from the graphs, as inhibition induced by high concentrations of REL-1017 (e.g., 50 µM) cannot be overcome even by agonist concentrations as high as 1 mM L-glutamate. RFU is relative fluorescence units.CC BY · PubMed Central
Figure 3 10 µM REL-1017 differentially blocked heterodimeric NMDARs in the presence of extracellular 1 mM Mg2+. REL-1017 showed a preference for NMDARs containing the 2D subunit, which is blocked in the presence of either 10 μM or 1 μM L-glutamate at −30 mV or more negative voltages. Data were obtained in automated patch-clamp platform. Every data point represents mean ± SEM (n = 4) of normalized current elicited by 10 mM L-glutamate at indicated voltage, measured during a hyperpolarizing ramp, in the absence (○) or presence (●) of 10 µM REL-1017. Statistical results of one-way analysis of variance (ANOVA) followed by Tukey’s multiple comparisons test also reported p < 0.05 (*), p < 0.01 (**), p < 0.001 (***), and p < 0.0001 (****). Glu is glutamate.
Figure 3 10 µM REL-1017 differentially blocked heterodimeric NMDARs in the presence of extracellular 1 mM Mg2+. REL-1017 showed a preference for NMDARs containing the 2D subunit, which is blocked in the presence of either 10 μM or 1 μM L-glutamate at −30 mV or more negative voltages. Data were obtained in automated patch-clamp platform. Every data point represents mean ± SEM (n = 4) of normalized current elicited by 10 mM L-glutamate at indicated voltage, measured during a hyperpolarizing ramp, in the absence (○) or presence (●) of 10 µM REL-1017. Statistical results of one-way analysis of variance (ANOVA) followed by Tukey’s multiple comparisons test also reported p < 0.05 (*), p < 0.01 (**), p < 0.001 (***), and p < 0.0001 (****). Glu is glutamate.CC BY · PubMed Central
Figure 4 Experiments were conducted using whole-cell patch-clamp electrophysiology at a −70 mV holding potential. Concentrations of (±)-ketamine able to inhibit 75% of the current elicited by 10 µM glutamate and glycine each were applied to a cell line expressing heterodimeric NR1-2C NMDARs to carry out kinetic studies. These experiments showed that 10 µM REL-1017 and 1 µM (±)-ketamine elicited similar current blockade of approximately 75%. Control current (100%) was induced by 10 µM L-glutamate and 10 µM glycine, respectively, and resulted in −594.2 ± 103.7 pA (mean ± SEM, n = 28). 10 µM REL-1017 and 10 µM, 3 µM, 1 µM, and 0.3 µM (±)-ketamine reduced L-glutamate/glycine–elicited current by 74.6 ± 1.9% (n = 12), 97.2 ± 0.3% (n = 3), 89.7 ± 0.6% (n = 3), 74.6 ± 2.2% (n = 3), and 44.2 ± 3.0% (n = 7), respectively.
Figure 4 Experiments were conducted using whole-cell patch-clamp electrophysiology at a −70 mV holding potential. Concentrations of (±)-ketamine able to inhibit 75% of the current elicited by 10 µM glutamate and glycine each were applied to a cell line expressing heterodimeric NR1-2C NMDARs to carry out kinetic studies. These experiments showed that 10 µM REL-1017 and 1 µM (±)-ketamine elicited similar current blockade of approximately 75%. Control current (100%) was induced by 10 µM L-glutamate and 10 µM glycine, respectively, and resulted in −594.2 ± 103.7 pA (mean ± SEM, n = 28). 10 µM REL-1017 and 10 µM, 3 µM, 1 µM, and 0.3 µM (±)-ketamine reduced L-glutamate/glycine–elicited current by 74.6 ± 1.9% (n = 12), 97.2 ± 0.3% (n = 3), 89.7 ± 0.6% (n = 3), 74.6 ± 2.2% (n = 3), and 44.2 ± 3.0% (n = 7), respectively.CC BY · PubMed Central
Figure 5 Sample traces of 10 µM REL-1017 and 1 µM (±)-ketamine onset and offset kinetics. Experiments were conducted by whole-cell patch-clamp electrophysiology at a −70 mV holding potential in NR1-2C–expressing CHO cells. A protocol was established to measure how fast REL-1017 blockade of NMDAR-mediated currents can be established (onset kinetic) and how fast this blockade can be removed (offset kinetic) by perfusion with a buffer containing the agonist L-glutamate but devoid of REL-1017. Test item application protocol diagram (top) and sample traces (bottom) of test item onset and offset kinetic experiments are shown with 10 µM REL-1017-treated cell (left) or 1 µM (±)-ketamine–treated cell (right). I0, I1, and I2 were the currents measured at the end of the first 5 s of 10 μM/10 μM L-glutamate/glycine application, the 30-s co-application with test item, and the final 50-s co-agonists application, respectively. In this case, s is seconds.
Figure 5 Sample traces of 10 µM REL-1017 and 1 µM (±)-ketamine onset and offset kinetics. Experiments were conducted by whole-cell patch-clamp electrophysiology at a −70 mV holding potential in NR1-2C–expressing CHO cells. A protocol was established to measure how fast REL-1017 blockade of NMDAR-mediated currents can be established (onset kinetic) and how fast this blockade can be removed (offset kinetic) by perfusion with a buffer containing the agonist L-glutamate but devoid of REL-1017. Test item application protocol diagram (top) and sample traces (bottom) of test item onset and offset kinetic experiments are shown with 10 µM REL-1017-treated cell (left) or 1 µM (±)-ketamine–treated cell (right). I0, I1, and I2 were the currents measured at the end of the first 5 s of 10 μM/10 μM L-glutamate/glycine application, the 30-s co-application with test item, and the final 50-s co-agonists application, respectively. In this case, s is seconds.CC BY · PubMed Central
Figure 6 Trapping experiments were conducted in whole-cell patch-clamp electrophysiology at −70 mV holding potential. Trapping experiments were designed to measure trapped block (BT) of 10 µM REL-1017 or 1 µM (±)-ketamine that is % ratio between residual block (BR) after extensive (85 s) cell wash with glycine alone and initial test item block (B). Test item application protocol diagram (top) and sample traces (bottom) of trapping experiments with 10 µM REL-1017-treated cell (left) or 1 µM (±)-ketamine-treated cell (right) are shown. I1st and I2nd were the peak currents measured within 1 s after onset of the first and second 10 µM/10µM L-glutamate/glycine addition, respectively. Results from trapping experiments are reported in Table 6. s is seconds.
Figure 6 Trapping experiments were conducted in whole-cell patch-clamp electrophysiology at −70 mV holding potential. Trapping experiments were designed to measure trapped block (BT) of 10 µM REL-1017 or 1 µM (±)-ketamine that is % ratio between residual block (BR) after extensive (85 s) cell wash with glycine alone and initial test item block (B). Test item application protocol diagram (top) and sample traces (bottom) of trapping experiments with 10 µM REL-1017-treated cell (left) or 1 µM (±)-ketamine-treated cell (right) are shown. I1st and I2nd were the peak currents measured within 1 s after onset of the first and second 10 µM/10µM L-glutamate/glycine addition, respectively. Results from trapping experiments are reported in Table 6. s is seconds.CC BY · PubMed Central
Figure 7 Structure of NR1-2D with drug binding site highlighted by a black box (A). The binding of esmethadone (B, light blue), arketamine (C, magenta), and esketamine (D, purple) in open (B–D, PDB code 6WHT) and closed (E–G, PDB code 6WHS) conformational states of NR1-2D are shown.
Figure 7 Structure of NR1-2D with drug binding site highlighted by a black box (A). The binding of esmethadone (B, light blue), arketamine (C, magenta), and esketamine (D, purple) in open (B–D, PDB code 6WHT) and closed (E–G, PDB code 6WHS) conformational states of NR1-2D are shown.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 48 references

Cited by

Metadata

Authors
Bettini, E., Stahl, S. M., De Martin, S., Mattarei, A., Sgrignani, J., Carignani, C., Nola, S., Locatelli, P., Pappagallo, M., Inturrisi, C. E., Bifari, F., Cavalli, A., Alimonti, A., Pani, L., Fava, M., Traversa, S., Folli, F., & Manfredi, P. L.
Affiliations
  • Aptuit (Italy) (IT)
  • University of California San Diego (US)
  • Department of Pharmaceutical and Pharmacological Sciences, University of Padua, 35122 Padua, Italy
  • University of Padua (IT)
  • Institute for Research in Biomedicine (CH)
  • Albert Einstein College of Medicine (US)
  • Relmada Therapeutics, Inc. (United States) (US)
  • University of Milan (IT)
  • SIB Swiss Institute of Bioinformatics (CH)
  • University of Modena and Reggio Emilia (IT)
  • Department of Psychiatry, Massachusetts General Hospital, Boston, MA 02114, USA
Corresponding author
Manfredi, Paolo L.
Venue
Pharmaceuticals
Publisher
MDPI AG
Published
2022-08-13
Volume
15
Issue
8
Pages
997
ISSN
1424-8247 (ISSN-L)
OpenAlex
W4291512787
Cited by
31
References
48
Citations by year
2026: 6 · 2025: 5 · 2024: 11 · 2023: 7 · 2022: 2
FWCI
2.76
Type
journal article
Language
en
Open access
Locations
  • Pharmaceuticals (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Repository for Publications and Research Data (ETH Zurich) (publishedVersion, cc-by)
  • Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, cc-by)
  • IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Repository for Publications and Research Data (ETH Zurich) (submittedVersion, cc-by)
  • Padua Research Archive (University of Padova) (submittedVersion, cc-by)
  • ETH Zürich Research Collection
Funders
Relmada Therapeutics (VDD9974)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
Keywords
NMDA receptor antagonists, major depressive disorder, dextromethorphan, memantine, ketamine, MK-801, calcium current, open channel conformation, drug binding affinity, psychotomimetic side effects, glutamate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.